GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Research & Development

Sandoz Group AG (FRA:D8Y0) Research & Development : €894 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Sandoz Group AG's Research & Development for the six months ended in Jun. 2024 was €454 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €894 Mil.

Sandoz Group AG Research & Development Historical Data

The historical data trend for Sandoz Group AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Research & Development Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Research & Development
786.35 849.14

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Research & Development - 412.58 439.24 454.28

Sandoz Group AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €894 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG  (FRA:D8Y0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sandoz Group AG Research & Development Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Research & Development
Comparable Companies
XSWX:SFZN XSWX:PPGN ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 HKSE:03692 NBIX NSE:DIVISLAB BOM:500124 VTRS SZSE:000963 XPAR:IPN SHSE:600085 XTAE:TEVA SHSE:600196
Traded in Other Exchanges
SDZXF:USA SDZNY:USA SDZz:UK 0SAN:UK D8Y0:Germany SDZ:Switzerland
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines